HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers

Antisense and Nucleic Acid Drug Development

Volumn 13, Issue 1, 2003, Pages 31-43

  Moulton, Hong M ^a   Hase, Michelle C ^a   Smith, Kristen M ^a   Iversen, Patrick L ^a  

^a AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; OLIGOMER; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; CONJUGATION; CONTROLLED STUDY; FLUORESCENCE; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; PRIORITY JOURNAL; RNA SEQUENCE; RNA SPLICING; RNA TRANSLATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0037302448     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729003764097322     Document Type: Article

References (43)

1. ARORA, V., KROEKER, A.D., REDDY, M.T., and IVERSEN, P.L. (2002). Cytochrome p450 3A2 antisense morpholino oligomer AVI-4472: A 14-day toxicity study in male rats. Toxicol. Sci. 66, 26 (abstract).
2. ASTRIAB-FISHER, A., SERGUEEV, D.S., FISHER, M., SHAW, B.R., and JULIANO, R.L. (2000). Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem. Pharmacol. 60, 83-90.
3. ASTRIAB-FISHER, A., SERGUEEV, D., FISHER, M., SHAW, B.R., and JULIANO, R.L. (2002). Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: Effects on cellular uptake, binding to target sequences, and biologic actions. Pharm. Res. 19, 744-754.
4. BEHRINGER, R., and MAGNUSON, T., eds. (2001). Genesis 30, July 30.
5. BRANDON, L.J., CHRISTENSSON, B., and SMITH, C.I. (2001). In vivo nuclear delivery of oligonucleotides via hybridizing bifunctional peptides. Gene Ther. 8, 84-87.
6. CHELLAIAH, M.A., SOGA, N., SWANSON, S., McALLISTER, S., ALVAREZ, U., WANG, D., DOWDY, S.F., and HRUSKA, K.A. (2000). Rho-A is critical for osteoclast podosome organization, motility, and bone resorption. J. Biol. Chem. 275, 11993-12002.
7. CHEN, L., WRIGHT, L.R., CHEN, C.H., OLIVER, S.F., WENDER, P.A., and MOCHLY-ROSEN, D. (2001). Molecular transporters for peptides: Delivery of a cardioprotective epsilon PKC agonist peptide into cells and intact ischemic heart using a transport system, R(7). Chem. Biol. 8, 1123-1129.
8. DEROSSI, D., JOLIOT, A.H., CHASSAING, G., and PROCHIANTZ, A. (1994). The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269, 10444-10450.
9. ERIKSSON, M., NIELSEN, P.E., and GOOD, L. (2002). Cell permeabilization and uptake of antisense peptide-peptide nucleic acid (PNA) into Escherichia coli. J. Biol. Chem. 277, 7144-7147.
10. FAWELL, S., SEERY, J., DAIKH, Y., MOORE, C., CHEN, L.L., PEPINSKY, B., and BARSOUM, J. (1994). Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA 91, 664-668.
11. GHOSH, C., and IVERSEN, P.L. (2000). Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers. Antisense Nucleic Acid Drug Dev. 10, 263-274.
12. GOOD, L., AWASTHI, S.K., DRYSELIUS, R., LARSSON, O., and NIELSEN, P.E. (2001). Bactericidal antisense effects of peptide-PNA conjugates. Nat. Biotechnol. 19, 360.
13. HEASMAN, J. (2002). Morpholino oligos: Making sense of antisense? Dev. Biol. 243, 209-214.
14. HEASMAN, J., KOFRON, M., and WYLIE, C. (2000). Beta-catenin signaling activity dissected in the early Xenopus embryo: A novel antisense approach. Dev. Biol. 222, 124-134.
15. HOWARD, E.W., NEWMAN, L.A., OLEKSYN, D.W., ANGERER, R.C., and ANGERER, L.M. (2001). SpKrl: A direct target of (beta)-catenin regulation required for endoderm differentiation in sea urchin embryos. Development 128, 365-375.
16. HUDZIAK, R.M., BAROFSKY, E., BAROFSKY, D.F., WELLER, D.L., HUANG, S.B., and WELLER, D.D. (1996). Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 6, 267-272.
17. HUDZIAK, R.M., SUMMERTON, J., WELLER, D.D., and IVERSEN, P.L. (2000). Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev. 10, 163-176.
18. IVERSEN, P.L. (2001). Phosphorodiamidate morpholino oligomers. In: Antisense Drug Technology. S.T. Crooke, ed. (Marcel Dekker, New York), pp. 375-389.
19. KANG, S.H., CHO, M.J., and KOLE, R. (1998). Up-regulation of luciferase gene expression with antisense oligonucleotides: Implications and applications in functional assay development. Biochemistry 73, 6235-6239.
20. KOPPELHUS, U., AWASTHI, S.K., ZACHAR, V., HOLST, H.U., EBBESEN, P., and NIELSEN, P.E. (2002). Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates. Antisense Nucleic Acid Drug Dev. 12, 51-63.
21. LEWIN, M., CARLESSO, N., TUNG, C.H., TANG, X.W., CORY, D., SCADDEN, D.T., and WEISSLEDER, R. (2000). Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18, 410-414.
22. MI, Z., MAI, J., LU, X., and ROBBINS, P.D. (2000). Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo. Mol. Ther. 2, 339-347.
23. MITCHELL, D.J., KIM, D.T., STEINMAN, L., FATHMAN, C.G., and ROTHBARD, J.B. (2000). Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Peptide Res. 56, 318-325.
24. MORCOS, P.A. (2001). Achieving efficient delivery of morpholino oligos in cultured cells. Genesis 30, 94-102.
25. MORRIS, M.C., DEPOLLIER, J., MERY, J., HEITZ, F., and DIVITA, G. (2001). A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 19, 1173-1176.
26. NASEVICIUS, A., and EKKER, S.C. (2000). Effective targeted gene "knockdown" in zebrafish. Nat. Genet. 26, 216-220.
27. NASEVICIUS, A., LARSON, J., and EKKER, S.C. (2000). Distinct requirements for zebrafish angiogenesis revealed by a VEGF-A morphant. Yeast 17, 294-301.
28. PARTRIDGE, M., VINCENT, A., MATTHEWS, P., PUMA, J., STEIN, D., and SUMMERTON, J. (1996). A simple method for delivering morpholino antisense oligos into the cytoplasm of cells. Antisense Nucleic Acid Drug Dev. 6, 169-175.
29. PICHON, C., MONSIGNY, M., and ROCHE, A.C. (1999). Intracellular localization of oligonucleotides: Influence of fixative protocols. Antisense Nucleic Acid Drug Dev. 9, 89-93.
30. POOGA, M., SOOMETS, U., HALLBRINK, M., VALKNA, A., SAAR, K., REZAEI, K., KAHL, U., HAO, J.X., XU, X.J., WIESENFELD-HALLIN, Z., HOKFELT, T., BARTFAI, T., and LANGEL, U. (1998). Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16, 857-861.
31. RICHARD, J.P., MELIKOV, K., VIVES, E., RAMOS, C., VERBEURE, B., GAIT, M.J., CHERNOMORDIK, L.V., and LEBLEU, B. (2003). Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278, 585-90.
32. ROTHBARD, J.B., KREIDER, E., VANDEUSEN, C.L., WRIGHT, L., WYLIE, B.L., and WENDER, P.A. (2002). Arginine-rich molecular transporters for drug delivery: Role of backbone spacing in cellular uptake. J. Med. Chem. 45, 3612-3618.
33. SCHWARZE, S.R., HO, A., VOCERO-AKBANI, A., and DOWDY, S.F. (1999). In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285, 1569-1572.
34. STEIN, D., FOSTER, E., HUANG, S.B., WELLER, D., and SUMMERTON, J. (1997). A specificity comparison of four antisense types: Morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. 7, 151-157.
35. STEIN, D.A., SKILLING, D.E., IVERSEN, P.L., and SMITH, A.W. (2001). Inhibition of vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 11, 317-325.
36. SUMMERTON, J. (1999). Morpholino antisense oligomers: The case for an RNase H-independent structural type. Biochim. Biophys. Acta 1489, 141-158.
37. SUMMERTON, J., and WELLER, D. (1993). Uncharged morpholino-based polymers having phosphorus containing chiral intersubunit linkages. US Patent 5,185,444.
38. SUMMERTON, J., and WELLER, D. (1997). Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7, 187-195.
39. SUMMERTON, J., STEIN, D., HUANG, S.B., MATTHEWS, P., WELLER, D., and PARTRIDGE, M. (1997). Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev. 7, 63-70.
40. TAYLOR, M.F., PAULAUSKIS, J.D., WELLER, D.D., and KOBZIK, L. (1996). In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor-alpha mRNA. J. Biol. Chem. 271, 17445-17452.
41. TAYLOR, M.F., PAULAUSKIS, J.D., WELLER, D.D., and KOBZIK, L. (1997). Comparison of efficacy of antisense oligomers directed toward TNF-alpha in helper T and macrophage cell lines. Cytokine 9, 672-681.
42. VIVES, E., BRODIN, P., and LEBLEU, B. (1997). A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272, 16010-16017.
43. WENDER, P.A., MITCHELL, D.J., PATTABIRAMAN, K., PELKEY, E.T., STEINMAN, L., and ROTHBARD, J.B. (2000). The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc. Natl. Acad. Sci. USA 97, 13003-13008.